Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this news hasn’t made a big splash in myositis circles, but it should. Vamorolone, marketed under the name Agamree, is a corticosteroid drug with a twist….
Continue Reading
Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Trial of Intravenous Immune Globulin in Dermatomyositis”) Click here for more details
Continue Reading
Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically meaningful improvement however, zetomipzomib did not demonstrate a significant differentiation from the placebo. We will learn more from this study with additional deeper analysis in…
Continue Reading
Clinical Research Manager, Myositis Discovery Programme Centre for Molecular Medicine and Innovative Therapeutics (CMMIT) Murdoch University, Perth, Australia Her program and discussion will include: Upcoming Research Opportunities Current Active Research Recently Closed Research Click here to view presentation
Continue Reading
The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis! The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous…
Continue Reading